Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.50 | -0.93 | 11.92 | -0.64 |
| FCF Yield | -3.54% | -3.67% | -4.40% | -2.75% |
| EV / EBITDA | -34.69 | -21.92 | -23.87 | -37.95 |
| Quality | ||||
| ROIC | -20.40% | -37.35% | -19.87% | -8.41% |
| Gross Margin | 97.74% | 95.54% | 96.81% | 96.54% |
| Cash Conversion Ratio | 1.06 | 0.83 | 1.22 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 50.41% | -12.32% | 156.43% | 224.03% |
| Free Cash Flow Growth | 48.63% | 5.66% | -12.85% | -137.07% |
| Safety | ||||
| Net Debt / EBITDA | 4.49 | 1.91 | 3.72 | 3.50 |
| Interest Coverage | -52.81 | -159.93 | -40.84 | -8.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,335.41 | -11,916.03 | -8,428.16 | -8,670.57 |